your partner that cares

Value Added Medicines
Oromucosal Delivery
Complex Injectables

bluepharma 20 years
Oromucosal delivery

BlueOS® and BluEase™ are innovative and versatile platforms for the delivery of drug substances through the oral mucosa and gastrointestinal tract.

These patient centric technologies enable both the incorporation of New Chemical Entities and the repurposing of known drugs, including off patent molecules.

Crossing boundaries towards patients’ needs, prescribers’ confidence and payers’ outcomes.

**CONVENIENCE**
Allowing patients and caregivers to succeed:
- Patients with dysphagia and difficulties to swallow, such as pediatrics and geriatrics.
- Emergency situations and non-collaborative patients.
- On-the-go solution.

**ADHERENCE AND SAFETY**
Giving confidence to prescribers:
- Improved convenience resulting in improved adherence.
- Potential to be less invasive as compared to existing solutions.
- Potential for improved bioavailability and fast onset of action.

**SAVINGS**
Improved adherence allows for better outcomes and less visits to the hospital, representing savings to payers.

**Intellectual Property**
Bluepharma solely owns proprietary technology for oral thin films (BlueOS®) and buccal sprays (BluEase™) formulations, submitted and granted in major territories worldwide.
Potential Applications

<table>
<thead>
<tr>
<th>THERAPEUTIC AREAS</th>
<th>INDICATIONS (EXAMPLES)</th>
</tr>
</thead>
</table>
| Central Nervous System     | Amyotrophic Lateral Sclerosis  
Epilepsy  
Parkinson’s Disease  
Dementia  
Tardive Dyskinesia                                                                                                                                                                                                                     |
| Chronic diseases           | Migraine  
Opioid Overdose  
Alcohol Use Disorder                                                                                                                                                                                                                                                                         |
| Addiction                  | Short-term Sedation                                                                                                                                                                                                                                                                                                                                                                                                       |

**Value Proposition**

- Dose accuracy
- Easy and convenient administration (pediatrics/dysphagia/elderly/non-collaborative)
- No need for water
- On the go, portable and discrete solution
- Improved compliance
- Non-invasive solution
- Rapid onset of action
- Direct entry into systemic circulation (applicable to sublingual applications)
Complex Injectables

Complex injectables offer unique advantages and solve major challenges of conventional oral or parenteral drug delivery systems.

Complex Injectables
BlueCi™

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>VALUE PROPOSITION</th>
<th>TYPE OF FORMULATION</th>
</tr>
</thead>
</table>
| Oncology Mesothelioma| • Improved SAFETY and EFFICACY  
                                 • IP granted in major markets WW  
                                 • Orphan Drug Designation granted by FDA and EMA (Mesothelioma) | Liposomal           |
| Postoperative Pain   | • Polymer based Long Acting Injectable  
                                 • Improved SAFETY (Opioid free)  
                                 • Potential for readministration | Long-acting injectable |

Technical POC  
Formulation Development  
Non-clinical POC  
Clinical POC  
Scale-up

ongoing
ongoing

Create value through Innovation.

How? Contact us!

For business inquiries: business@bluepharma.pt  
S. Martinho do Bispo · 3045–016 Coimbra · PORTUGAL  
Tel. +351 239 800 300 · Fax +351 239 800 333

www.bluepharmagroup.com

Bluepharma’s facilities are EU-GMP certified and approved by MFDS (Republic of Korea), ANVISA (Brazil), MOH Libya, SFDA (Kingdom of Saudi Arabia), Minpromtorg (Russian Federation) and by US FDA (2009, 2012, 2014, 2016, 2019).

We are registered in Iraq, Jordan, Kurdistan, Taiwan, UAE and Vietnam.